Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Verastem Inc (NASDAQ:VSTM)

1.37
Delayed Data
As of 11:50am ET
 -0.01 / -0.72%
Today’s Change
1.05
Today|||52-Week Range
6.81
-26.34%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$51.0M

Company Description

Verastem, Inc. is a clinical biopharmaceutical company, which is focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. The company is developing small molecule inhibitors of signaling pathways which includes Focal Adhesion Kinase FAK, PI3K/mTOR and Wnt that are critical to cancer stem cell survival and proliferation. Verastem was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg and Christoph H. Westphal on August 4, 2010 and is headquartered in Cambridge, MA.

Contact Information

Verastem, Inc.
117 Kendrick Street
Needham Massachusetts 02494
P:(781) 292-4200
Investor Relations:
(781) 292-4214

Employees

Shareholders

Mutual fund holders8.30%
Individual stakeholders28.85%
Other institutional23.47%

Top Executives

Robert M. ForresterPresident, Chief Executive Officer & Director
Dan PatersonChief Operating Officer
Joe ChiapponiTreasurer, Chief Financial & Accounting Officer
Jonathan PachterChief Scientific Officer
Gregory I. BerkChief Medical Officer